Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years
Authors:
- 1 August 2019
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 168, 61-67
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 39 references indexed in Scilit:
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Natural history of chronic hepatitis B REVEALedJournal of Gastroenterology and Hepatology, 2011
- A Patient with Chronic Hepatitis B and Regression of Fibrosis during TreatmentSeminars in Liver Disease, 2010
- Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patientsLiver International, 2010
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003
- The role of liver biopsy in chronic hepatitis CHepatology, 2002
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981